SCHEDULE: Empery Asset Management Discloses 7.57% Passive Stake in Outlook Therapeutics

Empery Asset Management, LP, along with its managing members Ryan M. Lane and Martin D. Hoe, reported a 7.57% beneficial ownership stake in Outlook Therapeutics, Inc. common stock.

Summary

• Empery Asset Management, LP, Ryan M. Lane, and Martin D. Hoe collectively reported beneficial ownership of 3,195,641 shares of Outlook Therapeutics, Inc. common stock.
• This ownership represents 7.57% of the total outstanding common stock of Outlook Therapeutics, Inc.
• The percentage is calculated based on 42,192,728 shares of common stock outstanding as of May 23, 2025, as reported in the company's Prospectus Supplement.
• Empery Asset Management, LP serves as the investment manager for the funds holding these shares.
• Ryan M. Lane and Martin D. Hoe are Managing Members of Empery AM GP, LLC, the general partner of Empery Asset Management, LP, and are deemed beneficial owners due to their investment discretion.
• The shares were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing the control of Outlook Therapeutics, Inc.

Sentiment

Score: 6

Explanation: The filing is a factual disclosure of a significant passive ownership stake by an institutional investor. While not directly impacting the company's operations or financials, it can be viewed as a neutral to slightly positive signal of institutional interest and confidence in the issuer.

Positives

• The disclosure of a significant passive stake by an institutional investment manager like Empery Asset Management may signal institutional confidence or interest in Outlook Therapeutics, Inc.

Future Outlook

This filing is a disclosure of beneficial ownership by an investment manager and its principals and does not contain forward-looking statements or guidance from Outlook Therapeutics, Inc.

Management Comments

• Empery Asset Management, LP, Ryan M. Lane, and Martin D. Hoe certified that the securities were acquired and are held in the ordinary course of business and not for the purpose or with the effect of changing or influencing the control of the issuer.

Industry Context

The filing indicates that an institutional investment firm, Empery Asset Management, has taken a significant passive stake in Outlook Therapeutics, Inc., a company likely operating in the biotechnology or pharmaceutical sector given its name. This suggests ongoing institutional interest in companies within this industry.

Comparison to Industry Standards

• This filing is a standard Schedule 13G, which is a regulatory requirement for passive investors acquiring more than 5% of a company's stock. The reported 7.57% stake is a notable institutional position, comparable to other significant passive investments seen across the biotech and pharmaceutical sectors by investment funds like BlackRock, Vanguard, or Fidelity, which frequently disclose similar passive stakes in publicly traded companies.

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding a significant institutional holder, which can influence market perception and potentially liquidity.
• Company Management: Awareness of a large passive institutional investor may influence strategic considerations, though the filing explicitly states no intent to influence control.

Next Steps

• The reporting persons will be required to file amendments to this Schedule 13G if there are material changes to their beneficial ownership, such as an increase or decrease of 1% or more.

Key Dates

Keywords

Outlook Therapeutics, Empery Asset Management, Institutional Ownership, Schedule 13G, Common Stock, Beneficial Ownership, Investment Management, Shareholding